Table 1.
Demographic and clinical characteristics at the time of FDG PET and VOI measurements.
| Fallers | Non‐fallers | HC |
P value Fallers vs. Non‐fallers |
P value Fallers vs. HC |
P value Non‐fallers vs. HC |
|
|---|---|---|---|---|---|---|
| Sex (F/M) | 3/8 | 6/13 | 5/7 | 0.8041 | 0.4691 | 0.5681 |
| Age (years) | 63.64 ± 8.62 | 62.63 ± 9.04 | 61.75 ± 14.28 | 0.9672 | 0.9062 | 0.9732 |
| Disease duration (years) | 7.09 ± 4.18 | 8.16 ± 4.50 | – | 0.4623 | – | – |
|
UPDRS‐III (score 0 to 108) |
34.64 ± 14.18 | 31.52 ± 12.87 | – | 0.5463 | – | – |
| LEDD (mg) | 840.0 ± 386.11 | 783.16 ± 311.24 | – | 0.6624 | – | – |
| Left parietal lobe (SUVR) | 1.03 ± 0.10 | 1.20 ± 0.10 | 1.16 ± 0.12 | <0.0012 | 0.0162 | 0.6792 |
| Left cerebellum, post. lobe, tuber of vermis (SUVR) | 1.16 ± 0.08 | 1.05 ± 0.11 | 1.05 ± 0.07 | 0.0072 | 0.0132 | 0.9942 |
| Right cerebellum, ant. lobe (SUVR) | 1.20 ± 0.07 | 1.11 ± 0.07 | 1.11 ± 0.09 | 0.0102 | 0.0182 | 0.9982 |
Data are presented as mean ± standard deviation and corresponding p values (1Pearson’s chi‐square test, 2ANOVA and Tukey‐Kramer HSD test, 3Wilcoxon test, 4Student t‐test).